Cargando…

Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats

OBJECTIVE: Fibrates are used as lipid-lowering drugs and are well tolerated as cotreatments when glucose metabolism disturbances are also present. Synthetic glucocorticoids (GCs) are diabetogenic drugs that cause dyslipidemia, dysglycemia, glucose intolerance, and insulin resistance when in excess....

Descripción completa

Detalles Bibliográficos
Autores principales: Inácio, Maiara Destro, Rafacho, Alex, de Paula Camaforte, Nathália Aparecida, Teixeira, Poliana, Vareda, Priscilla Maria Ponce, Violato, Natália Moretti, Bosqueiro, José Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250034/
https://www.ncbi.nlm.nih.gov/pubmed/30532777
http://dx.doi.org/10.1155/2018/3257812
_version_ 1783372878172913664
author Inácio, Maiara Destro
Rafacho, Alex
de Paula Camaforte, Nathália Aparecida
Teixeira, Poliana
Vareda, Priscilla Maria Ponce
Violato, Natália Moretti
Bosqueiro, José Roberto
author_facet Inácio, Maiara Destro
Rafacho, Alex
de Paula Camaforte, Nathália Aparecida
Teixeira, Poliana
Vareda, Priscilla Maria Ponce
Violato, Natália Moretti
Bosqueiro, José Roberto
author_sort Inácio, Maiara Destro
collection PubMed
description OBJECTIVE: Fibrates are used as lipid-lowering drugs and are well tolerated as cotreatments when glucose metabolism disturbances are also present. Synthetic glucocorticoids (GCs) are diabetogenic drugs that cause dyslipidemia, dysglycemia, glucose intolerance, and insulin resistance when in excess. Thus, we aimed to describe the potential of bezafibrate in preventing or attenuating the adverse effects of GCs on glucose and lipid homeostasis. METHODS: Male Wistar rats were treated with high-dose bezafibrate (300 mg/kg, body mass (b.m.)) daily for 28 consecutive days. In the last five days, the rats were also treated with dexamethasone (1 mg/kg, b.m.). RESULTS: Dexamethasone treatment reduced the body mass gain and food intake, and bezafibrate treatment exerted no impact on these parameters. GC treatment caused an augmentation in fasting and fed glycemia, plasma triacylglycerol and nonesterified fatty acids, and insulinemia, and bezafibrate treatment completely prevented the elevation in plasma triacylglycerol and attenuated all other parameters. Insulin resistance and glucose intolerance induced by GC treatment were abolished and attenuated, respectively, by bezafibrate treatment. CONCLUSION: High-dose bezafibrate treatment prevents the increase in plasma triacylglycerol and the development of insulin resistance and attenuates glucose intolerance in rats caused by GC treatment, indicating the involvement of dyslipidemia in the GC-induced insulin resistance.
format Online
Article
Text
id pubmed-6250034
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62500342018-12-09 Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats Inácio, Maiara Destro Rafacho, Alex de Paula Camaforte, Nathália Aparecida Teixeira, Poliana Vareda, Priscilla Maria Ponce Violato, Natália Moretti Bosqueiro, José Roberto Int J Endocrinol Research Article OBJECTIVE: Fibrates are used as lipid-lowering drugs and are well tolerated as cotreatments when glucose metabolism disturbances are also present. Synthetic glucocorticoids (GCs) are diabetogenic drugs that cause dyslipidemia, dysglycemia, glucose intolerance, and insulin resistance when in excess. Thus, we aimed to describe the potential of bezafibrate in preventing or attenuating the adverse effects of GCs on glucose and lipid homeostasis. METHODS: Male Wistar rats were treated with high-dose bezafibrate (300 mg/kg, body mass (b.m.)) daily for 28 consecutive days. In the last five days, the rats were also treated with dexamethasone (1 mg/kg, b.m.). RESULTS: Dexamethasone treatment reduced the body mass gain and food intake, and bezafibrate treatment exerted no impact on these parameters. GC treatment caused an augmentation in fasting and fed glycemia, plasma triacylglycerol and nonesterified fatty acids, and insulinemia, and bezafibrate treatment completely prevented the elevation in plasma triacylglycerol and attenuated all other parameters. Insulin resistance and glucose intolerance induced by GC treatment were abolished and attenuated, respectively, by bezafibrate treatment. CONCLUSION: High-dose bezafibrate treatment prevents the increase in plasma triacylglycerol and the development of insulin resistance and attenuates glucose intolerance in rats caused by GC treatment, indicating the involvement of dyslipidemia in the GC-induced insulin resistance. Hindawi 2018-11-08 /pmc/articles/PMC6250034/ /pubmed/30532777 http://dx.doi.org/10.1155/2018/3257812 Text en Copyright © 2018 Maiara Destro Inácio et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Inácio, Maiara Destro
Rafacho, Alex
de Paula Camaforte, Nathália Aparecida
Teixeira, Poliana
Vareda, Priscilla Maria Ponce
Violato, Natália Moretti
Bosqueiro, José Roberto
Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
title Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
title_full Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
title_fullStr Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
title_full_unstemmed Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
title_short Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
title_sort prevention of elevation in plasma triacylglycerol with high-dose bezafibrate treatment abolishes insulin resistance and attenuates glucose intolerance induced by short-term treatment with dexamethasone in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250034/
https://www.ncbi.nlm.nih.gov/pubmed/30532777
http://dx.doi.org/10.1155/2018/3257812
work_keys_str_mv AT inaciomaiaradestro preventionofelevationinplasmatriacylglycerolwithhighdosebezafibratetreatmentabolishesinsulinresistanceandattenuatesglucoseintoleranceinducedbyshorttermtreatmentwithdexamethasoneinrats
AT rafachoalex preventionofelevationinplasmatriacylglycerolwithhighdosebezafibratetreatmentabolishesinsulinresistanceandattenuatesglucoseintoleranceinducedbyshorttermtreatmentwithdexamethasoneinrats
AT depaulacamafortenathaliaaparecida preventionofelevationinplasmatriacylglycerolwithhighdosebezafibratetreatmentabolishesinsulinresistanceandattenuatesglucoseintoleranceinducedbyshorttermtreatmentwithdexamethasoneinrats
AT teixeirapoliana preventionofelevationinplasmatriacylglycerolwithhighdosebezafibratetreatmentabolishesinsulinresistanceandattenuatesglucoseintoleranceinducedbyshorttermtreatmentwithdexamethasoneinrats
AT varedapriscillamariaponce preventionofelevationinplasmatriacylglycerolwithhighdosebezafibratetreatmentabolishesinsulinresistanceandattenuatesglucoseintoleranceinducedbyshorttermtreatmentwithdexamethasoneinrats
AT violatonataliamoretti preventionofelevationinplasmatriacylglycerolwithhighdosebezafibratetreatmentabolishesinsulinresistanceandattenuatesglucoseintoleranceinducedbyshorttermtreatmentwithdexamethasoneinrats
AT bosqueirojoseroberto preventionofelevationinplasmatriacylglycerolwithhighdosebezafibratetreatmentabolishesinsulinresistanceandattenuatesglucoseintoleranceinducedbyshorttermtreatmentwithdexamethasoneinrats